ABSTRACT
An open label, randomized, comparative, interventional pilot study was done to assess the effect of Lekhana Basti (medicated enema) and Rechana Nasya Karma (Errhine therapy) in the management of Sthoulya with special reference to obesity. In the study 30 clinically diagnosed patient of either sex were randomly divided into two groups. In Basti group, Lekhana Basti in Karma Basti manner was given for 30 days. Anuvasana Basti (enema with Triphaladi Taila) in the dose of 120 mL and Asthapana Basti (enema with Triphaladi decoction etc.) in the dose of approximately 960 mL was given. In Nasya group, Rechananasya on alternate days was given with Triphaladi (oil) in the dose of 0.5 mL per nostril for total 28 days. The patients were assessed on objective criteria such as such as weight, chest circumference, mid-arm circumference, mid-thigh circumference, triceps skin fold thickness, sub-scapular skin fold thickness, abdominal skin fold thickness, waist-hip ratio and lipid profile. It was observed that Basti group was a better intervention in providing relief, however there intergroup standard deviation was low on most of the variable expect the lipid profile. The results suggest that the Nasya Karma may be developed as a better practical approach in obesity management.
ABSTRACT
BACKGROUND: Dyslipidemia, a major risk factor of coronary heart disease, is the leading single cause of death in the world. Currently available hypolipidemic agents have been associated with a large number of side effects. The radical Ayurveda Samshodhana Chikitsa as a treatment protocol can provide better effect. Therefore, the present study was designed to evaluate the effect of Virechana Karma and Lekhana Basti in dyslipidemia. OBJECTIVES: To evaluate the effect of Virechana Karma and Lekhana Basti in the management of dyslipidemia (Medoroga). MATERIALS AND METHODS: Ninety patients of either sex in the age group of 20-60 years, fulfilling the study criteria were included in the study. The patients were randomly divided into three groups (thirty patients each). Virechana Karma was administered to patients in group A, Lekhana Basti was administered in group B and tablet Atorvastatin in group C. The effect of treatment was assessed by analyzing the complete lipid profile after completion of treatment and after the follow up in comparison to base line score. RESULTS: All the three groups showed statistically highly significant result in the lipid profile after the treatment and after the follow up. CONCLUSION: Virechana Karma is effective in reducing triglycerides level, where as Lekhana Basti is effective in reducing the cholesterol level in particular.
ABSTRACT
Lekhana Basti (medicated enema) is a Tikshna formulation which is basically aimed for Apatarpana of the body. The present study (medicated enema) was undertaken to evaluate its anti-hyperlipidemic activity in diet-induced hyperlipidemia animals. Parameters like changes in body weight, organ weight, serum total cholesterol, serum triglyceride, serum HDL cholesterol, and serum (LDL + VLDL) cholesterol were studied to assess the effect of therapy in comparison to the control groups. Lekhana Basti was found to be ineffective in producing anti-hyperlipidemic action potently, but still found to have cytoprotective activity against hyperlipidemia induced organ damage, which was also confirmed by attenuation of cell infiltration and microfatty changes on histopathological examination.
ABSTRACT
Hyperlipidemia is highly prevalent and is closely related to coronary heart disease which is the most common cause of death. Raised cholesterol is estimated to be responsible for 18% of cerebrovascular disease and 56% of ischemic heart disease. Overall, these diseases account for about 4.4 million deaths (7.9% of the total). Based upon the etiological factors and symptom complexes, hyperlipidemia can be considered as a part of Medoroga. Being a Tikshna formulation, the treatment modality of Lekhana Basti is aimed basically for Apatarpana (emaciation) of the body, as Basti is the fastest Apatarpana. In the present clinical trial, a total of 22 patients were registered of whom 19 patients completed the course of the therapy. Under randomization, the registered patients were divided into two groups of which group A was treated with Lekhana Basti and group B was administered standard control drug, i.e., Triphala Guggulu, for 21 days. The results of the study revealed that in patients treated with Lekhana Basti, there was a decrease of about 4.99% in S. cholesterol, 9.13% in S. low density lipoprotein (LDL), and 0.36% in S. apolipoprotein B. Lekhana Basti was found to have significant effect in reducing the symptoms of Medodushti and in reduction of objective parameters like weight, body mass index (BMI), body fat percentage, body circumferences such as chest, abdomen, hip, pelvis, mid-thigh circumference, etc., and skin fold thickness as biceps, triceps, mid-arm, and abdominal skinfold thickness.
ABSTRACT
Basti therapy is used widely for treatment of various diseases in the field of Ayurveda with several proven clinical applications, however; the exact mechanism through which the benefits are obtained are yet to be ascertained in the light of the contemporary developments in clinical science. It is also not clear that when administered Basti the active principles in the formulation gain entry in to the systemic circulation or not. The present study was planned to acquire some preliminary data with regards to the absorption of phytochemical constituents of the formulations when administered in the form of Basti. Gallic acid was used as marker compound and it's absorption in systemic circulation was assessed using high performance liquid chromatography. Gallic acid present in Lekhana Basti (Emaciating/ Desiccating Medicated Enema) was found to get absorbed in to systemic circulation. Maximum concentration in serum was seen in the animal which received Lekhana Basti with Prakshepa Dravya ( Catalytic Adjuvant) in comparison to animal which received Lekhana Basti without Prakshepa Dravya. Area under curve in chromatogram was also more in animal which received Lekhana Basti with Prakshepa Dravya. From primary evidence created by HPLC study it can be said that, phytochemicals of the Basti formulation do get absorbed in systemic circulation.